Development and molecular characterization of drug-polyelectrolyte complexes of sodium phenylbutyrate and phenylbutyric acid with Eudragit E PO for treatment of Urea Cycle Disorders

LUCIANI GIACOBBE, LC; BOLATTI, FG; OLIVERA ME

Congreso; 7ma Reunión Internacional de Ciencias Farmacéuticas; 2023

Sodium phenylbutyrate (SPB), employed for the treatment of urea cycle disorders, exhibits an aversive flavor that undermines treatment adherence. Eudragit EPO (EuE), a cationic polyelectrolyte, can interact with acidic drugs, typically necessitating the incorporation of inorganic counterions to enhance compatibility. The formation of EuE-SPB or EuE-PBA (phenylbutyric acid) complexes emerges as a viable strategy to ameliorate the disagreeable taste, while conferring minimal risk of perturbing the oral absorption profile due to its aptitude to limit release under salivary conditions, which dissipate at pH